APA (7th ed.) Citation

DE, G., JR, I., MS, G., SB, G., M, M., E, F., . . . 3rd, B. H. (2020). Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(2), 364. https://doi.org/10.1158/1078-0432.CCR-18-3965

Chicago Style (17th ed.) Citation

DE, Gerber, et al. "Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 26, no. 2 (2020): 364. https://doi.org/10.1158/1078-0432.CCR-18-3965.

MLA (9th ed.) Citation

DE, Gerber, et al. "Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 26, no. 2, 2020, p. 364, https://doi.org/10.1158/1078-0432.CCR-18-3965.